Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label AMG 479 in recurrent platinum-sensitive ovarian cancer
2008-001552-44Phase 2Completed
- Sponsor
- TRIO
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ganitumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by TRIO. Primary endpoints: Overall response rate and Clinical benefit response. Started Aug 2008; status: completed.
02
Drugs
ganitumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2008-001552-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001552-44.